Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Mogamulizumab→

Mogamulizumab Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
1159266-37-1
Molecular formula
Not available
Molecular weight
Not available
Drug class
Monoclonal AntibodyChemokine Receptor Type 4 InteractionMonoclonal antibody / antibody–drug conjugateAntibodies, Monoclonal
Mechanism of action
Chemokine Receptor Type 4 Interactions [MoA]
Indications / reported uses
  • Mycosis Fungoides
  • Sezary Syndrome
  • adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy
  • adult patients with relapsed or refractory mycosis fungoides or Sézary syndrome after at least one prior systemic therapy ( 1 )

Sources: FDA product labels (openFDA) · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Mogamulizumab Environmental Risk Assessment (ERA) (the Mogamulizumab ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.